Harvard Bioscience (HBIO) Current Assets (2010 - 2026)

Harvard Bioscience (HBIO) has 17 years of Current Assets data on file, last reported at $47.5 million in Q1 2026.

• Current Assets for Q1 2026 came in at $47.5 million, up 5.74% year-over-year; the trailing twelve-month figure through Mar 2026 was $47.5 million (up 5.74% YoY), and the FY2025 annual result was $48.2 million, up 6.89% from the prior year.
• Current Assets eased to $47.5 million in Q1 2026 per HBIO's latest filing, from $48.2 million in the prior quarter.
• Over five years, Current Assets peaked at $59.4 million in Q1 2022 and troughed at $43.8 million in Q3 2025.
• A 5-year average of $49.4 million and a median of $48.2 million in 2025 frame the typical range for Current Assets.
• On a YoY basis, Current Assets climbed as much as 20.77% in 2022 and fell as far as 16.98% in 2022.
• A 5-year view of Current Assets shows it stood at $51.1 million in 2022, then fell by 4.08% to $49.0 million in 2023, then declined by 8.0% to $45.1 million in 2024, then rose by 6.89% to $48.2 million in 2025, then slipped by 1.55% to $47.5 million in 2026.
• Business Quant data shows HBIO's Current Assets at $47.5 million in Q1 2026, $48.2 million in Q4 2025, and $43.8 million in Q3 2025.